Revolution Medicines, Inc. (NASDAQ:RVMD – Get Free Report) insider Mark A. Goldsmith sold 10,000 shares of the firm’s stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $44.93, for a total transaction of $449,300.00. Following the completion of the transaction, the insider now directly owns 300,170 shares in the company, valued at $13,486,638.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.
Revolution Medicines Stock Performance
Shares of RVMD stock opened at $47.32 on Friday. The company has a market capitalization of $7.90 billion, a P/E ratio of -12.62 and a beta of 1.43. The company’s 50 day moving average price is $43.69 and its two-hundred day moving average price is $40.09. Revolution Medicines, Inc. has a 52 week low of $15.44 and a 52 week high of $48.61.
Revolution Medicines (NASDAQ:RVMD – Get Free Report) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($0.04). The firm had revenue of $1.00 million for the quarter, compared to the consensus estimate of $0.81 million. During the same quarter in the previous year, the business earned ($0.92) EPS. The firm’s revenue was down 73.8% compared to the same quarter last year. Analysts forecast that Revolution Medicines, Inc. will post -3.35 earnings per share for the current year.
Institutional Trading of Revolution Medicines
Wall Street Analyst Weigh In
A number of brokerages recently weighed in on RVMD. Needham & Company LLC cut their price target on shares of Revolution Medicines from $62.00 to $61.00 and set a “buy” rating on the stock in a research report on Thursday, August 8th. Oppenheimer increased their price target on shares of Revolution Medicines from $45.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, July 16th. Bank of America increased their price target on shares of Revolution Medicines from $48.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 16th. Barclays increased their price target on shares of Revolution Medicines from $54.00 to $60.00 and gave the company an “overweight” rating in a research report on Friday, September 27th. Finally, HC Wainwright reiterated a “buy” rating and issued a $56.00 price target on shares of Revolution Medicines in a research report on Monday, August 12th. Ten analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Revolution Medicines currently has an average rating of “Buy” and an average target price of $54.00.
Read Our Latest Stock Analysis on Revolution Medicines
About Revolution Medicines
Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.
Featured Articles
- Five stocks we like better than Revolution Medicines
- How to Use the MarketBeat Dividend Calculator
- 3 Small-Cap Stocks on the Way to Bigger and Better Days
- What Are Growth Stocks and Investing in Them
- MarketBeat Week in Review – 9/30 – 10/4
- How to Calculate Return on Investment (ROI)
- Top Streaming Companies: Who’s Winning the Battle?
Receive News & Ratings for Revolution Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revolution Medicines and related companies with MarketBeat.com's FREE daily email newsletter.